Document Type : Original Article(s)


1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

5 Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

6 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

7 Assistant Professor, Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran


BACKGROUND: The oxidative stress is regarded as one of the main contributors to the health problem. Cyclooxygenase-2 (COX-2) and matrix metallopeptidase-9 (MMP-9) are two of the important genes that are reported to be involved in the cardiovascular disease (CVD) development in the molecular and genetic association studies. The aim of this study was to evaluate the level of expression of COX-2 and MMP-9 after selenium supplementation in patients with coronary artery disease (CAD).METHODS: In this sub-study of Selenegene study, subjects were randomly divided into groups, 19 subjects who received selenium and 22 patients with CAD who received placebo. Patients received either 200-mg selenium yeast tablets or placebo tablets after a meal, once daily for 60 days. The messenger ribonucleic acid (mRNA) levels of the selenium and prostaglandin-endoperoxide synthase 2 (PTGS2) (COX-2) and MMP-9 genes products were determined before and after the study.RESULTS: In this sub-study, 41 Iranian patients with CVD were enrolled (placebo group: n = 22, selenium intervention: n = 19). Fasting blood sugar (FBS) was higher among placebo group than selenium group (93.4 ± 12.7 vs. 124.4 ± 40.6 mg/dl, P = 0.03). Triglyceride (TG) level was higher among selenium group versus placebo group (123.3 ± 34.0 vs. 184.8 ± 69.4 mg/dl, P = 0.006). The data analysis demonstrated that the expression of MMP-9 and COX-2 genes did not change significantly in both selenium and placebo groups.CONCLUSION: This study showed a positive association between the expression of MMP-9 and COX-2 in the patients with CAD who received selenium but not the placebo groups. Yet, these findings need to be confirmed in further details and expanded sample size.


  1. Maleki A, Ghanavati R, Montazeri M, Forughi S, Nabatchi B. Prevalence of coronary artery disease and the associated risk factors in the adult population of Borujerd City, Iran. J Tehran Heart Cent 2019; 14(1): 1-5.
  2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349(9061): 1269-76.
  3. Benstoem C, Goetzenich A, Kraemer S, Borosch S, Manzanares W, Hardy G, et al. Selenium and its supplementation in cardiovascular disease-what do we know? Nutrients 2015; 7(5): 3094-118.
  4. Gharipour M, Sadeghi M, Behmanesh M, Salehi M, Nezafati P, Gharpour A. Selenium homeostasis and clustering of cardiovascular risk factors: A systematic review. Acta Biomed 2017; 88(3): 263-70.
  5. Faure P, Ramon O, Favier A, Halimi S. Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. Eur J Clin Invest 2004; 34(7): 475-81.
  6. Rayman MP, Stranges S. Epidemiology of selenium and type 2 diabetes: Can we make sense of it? Free Radic Biol Med 2013; 65: 1557-64.
  7. Bencsik P, Gomori K, Szabados T, Santha P, Helyes Z, Jancso G, et al. Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options. Br J Pharmacol 2020; 177(23): 5336-56.
  8. Vegiopoulos A, Muller-Decker K, Strzoda D, Schmitt I, Chichelnitskiy E, Ostertag A, et al. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 2010; 328(5982): 1158-61.
  9. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring) 2009; 17(6): 1150-7.
  10. Chan PC, Hsiao FC, Chang HM, Wabitsch M, Hsieh PS. Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance. FASEB J 2016; 30(6): 2282-97.
  11. Virdis A, Bacca A, Colucci R, Duranti E, Fornai M, Materazzi G, et al. Endothelial dysfunction in small arteries of essential hypertensive patients: Role of cyclooxygenase-2 in oxidative stress generation. Hypertension 2013; 62(2): 337-44.
  12. Ross S, Eikelboom J, Anand SS, Eriksson N, Gerstein HC, Mehta S, et al. Association of cyclooxygenase-2 genetic variant with cardiovascular disease. Eur Heart J 2014; 35(33): 2242-8a.
  13. Fang L, Du XJ, Gao XM, Dart AM. Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clin Sci (Lond) 2010; 119(4): 175-83.
  14. Hopps E, Caimi G. Matrix metalloproteinases in metabolic syndrome. Eur J Intern Med 2012; 23(2): 99-104.
  15. Sheikhvatan M, Boroumand MA, Behmanesh M, Ziaee S. Association of R279Q and C1562T polymorphisms of matrix metalloproteinase 9 gene and increased risk for myocardial infarction in patients with premature coronary artery disease. J Clin Lab Anal 2018; 32(1): e22218.
  16. Gharipour M, Sadeghi M, Behmanesh M, Salehi M, Roohafza H, Nezafati P, et al. Proposal of a study protocol of a preliminary double-blind randomized controlled trial. Verifying effects of selenium supplementation on selenoprotein p and s genes expression in protein and mRNA levels in subjects with coronary artery disease: Selenegene. Acta Biomed 2019; 90(1): 44-50.
  17. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004; 27(10): 2444-9.
  18. Hsieh PS, Tsai HC, Kuo CH, Chan JY, Shyu JF, Cheng WT, et al. Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats. Eur J Clin Invest 2008; 38(11): 812-9.
  19. Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, Ilveskoski E, Karhunen PJ, et al. COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: The Helsinki sudden death study. Mediators Inflamm 2008; 2008: 289453.
  20. Kirkby NS, Lundberg MH, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One 2014; 9(6): e98165.
  21. Scoditti E, Nestola A, Massaro M, Calabriso N, Storelli C, De Caterina R., et al. Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKCalpha and PKCbeta1 inhibition. Atherosclerosis 2014; 232(1): 17-24.
  22. Anwar K, Voloshyna I, Littlefield MJ, Carsons SE, Wirkowski PA, Jaber NL, et al. COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells. Lipids 2011; 46(2): 131-42.
  23. Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, Breyer RM, et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem 2006; 281(6): 3321-8.
  24. Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M, et al. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med 2006; 17(2): 357-62.
  25. Itatsu K, Sasaki M, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol 2009; 174(3): 829-41.
  26. Liu Z, Yao X, Du J, Song B, Zhang F. Selenium deficiency augments the levels of inflammatory factors and heat shock proteins via the redox regulatory pathway in the skeletal muscles of mice. Biol Trace Elem Res 2018; 182(2): 309-16.
  27. Hwang JT, Kim YM, Surh YJ, Baik HW, Lee SK, Ha J, et al. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res 2006; 66(20): 10057-63.
  28. Dhanjal NIK, Sharma S, Prabhu KS, Prakash NT. Selenium supplementation through Se-rich dietary matrices can upregulate the anti-inflammatory responses in lipopolysaccharide-stimulated murine macrophages. Food Agric Immunol 2017; 28(6): 1374-92.
  29. Li YB, Han JY, Jiang W, Wang J. Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells. Mol Biol Rep 2011; 38(4): 2301-6.
  30. Rooprai HK, Kyriazis I, Nuttall RK, Edwards DR, Zicha D, Aubyn D, et al. Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol 2007; 30(5): 1263-71.
  31. Chen YC, Prabhu KS, Mastro AM. Is selenium a potential treatment for cancer metastasis? Nutrients 2013; 5(4): 1149-68.